Moreover, the CANTOS trial, for the first time, showed that inhibition of inflammation using an antibody against Il-1β decreased cardiovascular events (172), providing further evidence for the importance of inflammation in atherosclerosis. The gene discussed is IL1B; the disease is atherosclerosis.